Since vaccines against infectious diseases traditionally have commanded significantly lower margins than pharmaceuticals, investors will be wanting to see PowderJect Pharmaceuticals plc demonstrate how its new vaccines-only focus will provide attractive returns.

PowderJect, which announced last week that it will divest the drugs and biologicals applications of its needleless powder injection delivery technology, believes it can command premium prices for its vaccines, both conventional ones that it reformulates for needleless delivery and novel DNA-based vaccines that it develops internally.